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AbsTrACT
Objective To investigate if chemokine expression 
patterns on leucocyte subsets influence the short-term 
anatomical treatment response of intravitreal antivascular 
endothelial growth factor therapy against neovascular age-
related macular degeneration (AMD).
Methods and analysis This study was conducted as 
a prospective observational cohort study of 79 patients 
with neovascular AMD. We used optical coherence 
tomography to quantify central retinal thickness (CRT) 
and to evaluate the presence of intraretinal and subretinal 
fluids in treatment-naive patients at baseline and after 
loading dose. Anatomical response was categorised into 
either good responders (complete regression of fluid or a 
reduction of >75% in CRT), partial responders (reduction 
of 0%–75% in CRT) or non-responders (increase of CRT). 
Expression levels of chemokine receptors (CCR1, CCR2, 
CCR3, CCR5, CXCR3 and CX3CR1) were measured on 
leucocyte subsets (monocytes, CD4 +T cells, and CD8 
+T cells) using flow cytometry. Finally, we explored 
potential correlation patterns of chemokine expression 
between the leucocyte subsets using group-specific 
correlation networks.
results Non-responders had higher CCR1 expression 
on monocytes (p=0.016) and lower CCR3 expression on 
CD8+ T cells (p=0.037). Correlation network analyses of 
chemokine receptor expression patterns on leucocyte 
subsets revealed intergroup differences.
Conclusion Short-term anatomical treatment response 
in neovascular AMD varies according to the leucocyte 
subset chemokine expression pattern, which confirms 
that immune dysfunction is a complex issue in AMD. Our 
results suggest that focusing on chemokines may be a 
relevant approach towards personalised treatment in 
neovascular AMD.
InTrOduCTIOn
Age-related macular degeneration (AMD) is 
the leading cause of legal blindness among 
the elderly in high-income countries, and 
prevalence is expected to increase signifi-
cantly in the near future due to demographic 
changes.1–3 The introduction of intravit-
real antivascular endothelial growth factor 
(VEGF) therapy has drastically improved the 
prognosis of neovascular AMD.3 Although the 
inhibition of VEGF generally in most cases at 
least stabilises vision and retinal morphology, 
some patients do not respond well to 
treatment.4 One explanation for the hetero-
geneous response to anti-VEGF therapy is that 
other angiogenic factors contribute to the 
development and sustainment of choroidal 
neovascularisations.5 Attention is needed on 
identifying other treatment targets than just 
VEGF to improve clinical outcomes in such 
patients.
Recent research has provided evidence 
of a systemic immunological component in 
AMD.6 Several alterations in the immune 
system of patients with AMD have been 
reported,7–17 including levels of chemokines 
and their receptors.12 14 16 17 Chemokines are 
signalling proteins secreted by cells, which 
Key messages
What is already known about this subject?
 ► Recent research has provided evidence of a system-
ic immunological component in age-related macular 
degeneration (AMD). Both the innate and the adap-
tive immune system are involved in the pathogenesis 
of AMD, but data on treatment response is sparse.
What are the new findings?
 ► Our findings demonstrate that non-responders af-
ter loading dose have a more complex peripheral 
chemokine receptor profile compared with good 
responders.
How might these results change the focus of 
research or clinical practice?
 ► These results implicate chemokines in antivas-
cular endothelial growth factor treatment failure 
and support the idea of systemic immunology as a 
component of neovascular AMD pathogenesis and 
progression. Focusing on chemokines may be a rel-
evant approach towards personalised treatment in 
neovascular AMD.
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induce chemotaxis towards a concentration gradient. 
Considering that chemokine receptors are expressed 
on leucocyte subsets that contribute to inflammation 
and angioneogenesis, one hypothesis is that the state of 
chemokine receptor expression on leucocyte subsets may 
contribute in a clinically important manner in neovas-
cular AMD.
In this study, we explored how patients with neovas-
cular AMD, stratified according to anti-VEGF treatment 
response, differ in terms of expression level of chemo-
kine receptors on leucocyte subsets and the complex 
interplay between leucocyte subset chemokine receptors.
MATerIAls And MeTHOds
Patient and public involvement
Patients were not involved in the design of this prospec-
tive observational cohort study. Patients were recruited 
from the outpatient retinal clinic of the Department of 
Ophthalmology, Zealand University Hospital, Denmark.
Participants and eligibility
All patients were subjected to a structured interview on 
medical history, current health conditions, medications 
and lifestyle factors. Smoking status was categorised as 
‘current’ (had smoked within the past year of inclusion), 
‘former’ (had a lifetime consumption of more than 100 
cigarettes) or ‘never’ smokers (less than 100 cigarettes 
ever). Alcohol consumption was registered as units (12 g 
ethanol) per week (self-reported). Physical activity was 
estimated from a single question previously validated7 18 
in patients with AMD.
All patients underwent thorough retinal examination 
by a trained ophthalmologist using slit-lamp examina-
tion, digital colour fundus photography (Carl-Zeiss, Jena, 
Germany), spectral-domain optical coherence tomog-
raphy (OCT), fundus autofluorescence imaging and 
retinal angiography with fluorescein and indocyanine 
green (Spectralis HRA-OCT, SLO Heidelberg Engi-
neering, Heidelberg, Germany). Diagnosis of neovascular 
AMD was made in cases with the copresence of drusen 
and fibrovascular pigment epithelium detachment and 
choroidal neovascular membrane with subretinal or 
sub-retinal pigment epithelium haemorrhages. Patients 
with signs of polypoidal choroidal vasculopathy or pachy-
choroid neovasculopathy were not included.
All newly diagnosed patients received a standard 
treatment regimen of three intravitreal anti-VEGF injec-
tions at 1-month intervals (‘loading dose’) followed by 
a clinical control approximately 2 months after the third 
injection. Blood samples were obtained when patients 
visited the clinic for follow-up retinal examination. Blood 
sampling was rescheduled if patients had received ranibi-
zumab within the past 4 weeks or aflibercept within the 
past 8 weeks, and blood was not sampled shortly after 
angiography in order to avoid influence on antibody 
staining.19 If a patient had two eyes eligible for the study, 
we included only data regarding the patient’s right eye.
In this study, we aimed to investigate chronic systemic 
changes, and to minimise interference, we did not sample 
blood from patients who had an ongoing infection. 
Patients who suffered from cancer or any immunolog-
ical disorders, or received immunomodulating treatment 
were excluded. We measured plasma C-reactive protein 
(CRP) to evaluate possible ongoing acute inflammation 
unknown to the patients and excluded patients with a 
CRP level of >15 mg/L. We also excluded patients with 
ungradable OCT quality as imaging measurements would 
be unreliable.
Imaging and analysis
OCT imaging and analysis were done using Heidelberg 
Eye Explorer V.1.9.10.0 (Heidelberg Engineering, Heidel-
berg, Germany). Each scan was composed of at least 19 
B-scans using automatic real-time tracking and B-scan 
averaging. Scan area was 20°×15° (5.7×4.3 mm), and the 
distance between B-scans was a maximum of 236 µm. 
Retinal thickness was measured from Bruch’s membrane 
to the inner limiting layer. The layer boundaries were 
manually corrected when needed. OCT images were 
analysed for central retinal thickness (CRT), defined as 
the average thickness of the central 1 mm of the retina 
using the Early Treatment Diabetic Retinopathy Study 
(ETDRS) Grid in Heidelberg Eye Explorer. We registered 
subretinal oedema (yes/no) and intraretinal oedema 
(yes/no), the latter defined as distinct intraretinal cysts.
definition of treatment response
Quantifiable definitions of anti-VEGF treatment response 
are classically based on change in best-corrected visual 
acuity (BCVA) or on morphological changes.20 In this 
study, we analysed morphological changes based on CRT. 
We compared OCT images from the day of diagnosis 
(baseline) to first clinical control following anti-VEGF 
loading dose (follow-up), as this clinical control has 
been shown to be a good predictor of how well patients 
respond to treatment over time.20–22
The response was categorised as ‘good’ (total regres-
sion of subretinal or intraretinal fluid or a reduction of 
>75% of baseline CRT), ‘partial’ (reduction of 0%–75% 
of baseline CRT) or ‘non-response’ (increase of CRT), 
based on the definitions by Amoaku et al.20
Chemokine receptor expression levels
We performed flow cytometric analysis on venous blood 
samples within 4 hours of phlebotomy. A blood volume 
containing 5×105 leucocytes (calculated using Sysmex 
KX-21N, Sysmex Corporation, Kobe, Japan) was sepa-
rated. Erythrocytes were lysed for 10 min with 10% red 
blood cell lysis buffer (Nordic Biosite AB, Täby, Sweden) 
in the dark at room temperature. Cells were then centri-
fuged at 500G and resuspended in isotonic buffer 
(IsoFlow Sheath Fluid; Beckman Coulter, Brea, CA, USA) 
three times. Fluorochrome-coupled antibodies were 
added to the solution (see online supplementary files 1 
and 2 for a complete list of antibodies). Corresponding 
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Figure 1 Gating strategy in flow cytometry analysis. (A) 
Identification of singlets using FSC-A versus FSC-H. (B) 
Subtyping of singlets into monocytes and lymphocytes 
using FSC-A versus SSC-A. (C) Isolation of CD4+/
CD8+ lymphocytes using fluorochrome-coupled specific 
antibodies. (D) Isolation of CD14+ monocytes using 
fluorochrome-coupled specific antibodies. (E) A general 
example of quantification of chemokine receptor (eg, CCR1) 
positive cells using a fluorescence histogram and a negative 
isotype control with a threshold of 1%. FSC-A, front scatter 
area; FSC-H, front scatter height; SSC-A, side scatter area.
isotype controls of each antibody was measured in a sepa-
rate tube. The sample was incubated in the dark at room 
temperature and was subsequently washed and resus-
pended in 600 µL isotonic buffer. Cells were analysed 
using the BD FACSCanto II flow cytometer (BD Biosci-
ences, Franklin Lakes, NJ, USA) and Kaluza Software 
V.1.5.20365.16139 (Beckman Coulter, Pasadena, CA, 
USA).
A forward scatter area versus a forward scatter height 
plot was used to identify singlets (figure 1A). Lympho-
cytes and monocytes were gated using a forward 
scatter area versus a side scatter area plot (figure 1B). 
Lymphocytes were further divided into CD4+ and CD8+ 
cells according to their expression of CD4 and CD8 
(figure 1C). Monocytes were similarly gated for CD14 
expression (figure 1D). For each of the three cell types, 
we identified chemokine receptor positive cells from a 
histogram of fluorescence from the respective fluoro-
chrome-coupled specific antibodies and used negative 
isotype controls (at 1% thresholds) to eliminate fluores-
cence noise from unspecific binding (figure 1E).
data analysis
Normally distributed data werepresented as mean and 
95% CIs and compared using the one-way analysis of 
variance. Not-normally distributed data were presented 
as median and IQR and were compared using the Krus-
kal-Wallis rank test. For categorical data, we used Fisher’s 
exact test. Correlation coefficients were calculated using 
Spearman’s rank (since chemokine receptor expression 
levels were not normally distributed). To calculate the 
OR of potential risk factors for treatment failure, univar-
iate logistic regression analyses were performed.
Statistical analysis was done using R V.3.4.2 for Mac 
OS X (The R Foundation for Statistical Computing, 
Vienna, Austria) and SPSS V.24.0.0.0, 32-bit edition. 
Group-specific correlation networks were drawn using 
the qgraph extension package for R V.1.4.4.23 Correlation 
coefficients with a value of 0.4–1.0 were included in the 
correlation networks with increasing edge width, indi-
cating a stronger correlation.
resulTs
Seventy-nine patients were enrolled in the study. We 
excluded 14 in total: 7 due to incomplete data, 1 due to 
poor OCT image quality, 3 due to interrupted treatment 
regimen and 3 due to CRP levels above 15 mg/L. This 
left 65 eligible patients for analysis. The group of patients 
with good response to treatment were older than the 
partial and non-responders (p=0.007) but did not differ 
significantly in other demographic or clinical character-
istics presented in table 1. Overall, patients’ Visual acuity 
improved; good morphological responders gained in 
average 7.0 letters (SD 9.8), partial responders gained in 
average 4.1 letters (SD 12.0) and non-responders gained 
3.5 letters (SD 8.6).
Chemokine receptor expression levels were compared 
between response groups as shown in table 2. We found 
that patients with no response to treatment had a higher 
proportion of CCR1+ monocytes (p=0.016) and a lower 
proportion of CD8+CCR3+ T cells (p=0.037).
The chemokine receptor expression levels on mono-
cytes, CD4+ T cells and CD8+ T cells were investigated 
using group-specific correlation networks (figure 2). 
These networks revealed several intergroup differences 
in chemokine receptor expression level correlations, 
thus suggesting a more complex systemic chemokine 
receptor expression pattern in patients with no response 
to anti-VEGF. In particular, we notice that expression of 
CCR2 on monocytes shifts towards a more central role in 
patients with a lack of response to treatment.
We found an age difference between groups, and this 
raised the question of whether the altered expression and 
increased complexity of the chemokine receptor correla-
tion network in the non-response group could be merely 
an age-related phenomenon. In order to investigate this 
issue, we calculated correlations between age and expres-
sion levels and found that age was not strongly correlated 
(rho<0.4, p>0.1) to any chemokine receptor expression 
level. We further divided all participants, regardless of 
treatment response, into tertiles (n=22, n=22, n=21) by 
age (ages ranging from 59–73 yars, 74–80 years and 81–93 
years). This revealed that the younger participants, in 
general, had a less complex chemokine receptor profile 
than the older ones, thus contradicting that young age 
could explain the observed increased complexity of the 
non-responders’ immune systems. Lastly, we performed 
the Kruskal-Wallis test on chemokine receptor expres-
sion level data while using the age categories instead of 
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Table 1 Baseline characteristics of participants in groups according to their response to anti-VEGF treatment
Response to anti-VEGF loading dose Good Partial Non-response P value
No. of patients, n 28 27 10
Demographic characteristics
  Age, mean (95% CI) 79.5 (76.9 to 82.2) 75.9 (72.7 to 79.0) 71.1 (67.4 to 74.8) 0.007*
  Females, % 60.7 51.9 40.0 0.534†
  Body mass index, mean (95% CI) 25.6 (23.7 to 27.3) 26.1 (24.0 to 28.3) 25.1 (21.0 to 29.2) 0.840*
  Smoking status
   Current, % 17.9 29.6 40.0 0.462†
   Former, % 46.4 44.4 50.0
   Never, % 35.7 25.9 10.0
  Alcohol (units/week), median (IQR) 3.8 (0.5–9) 6.0 (1.0–10.0) 3.5 (1.0–10.0) 0.828‡
  Regular exercise, % 57 63 70 0.789†
  Hypertension, % 64 41 40 0.174†
  Hypercholesterolaemia, % 43 19 20 0.125†
  Cardiovascular disease, % 32 22 30 0.702†
  Type 2 diabetes, % 18 4 0 0.152†
Retinal characteristics
  Central retinal thickness, µm, median 
(IQR)
385 (313–476) 432 (338–552) 412 (351–550) 0.475‡
  Best-corrected visual acuity (ETDRS 
letters), median (IQR)
69 (56–79) 63 (50–73) 61.5 (50–73) 0.264‡
  Intraretinal oedema, % 75 52 60 0.294†
  Subretinal oedema, % 71 93 90 0.063†
Treatment
  Aflibercept, % 71 48 50 0.187†
  Ranibizumab, % 29 52 50
*Analysis of variance.
†Fisher’s exact test.
‡Kruskal-Wallis test.
VEGF, vascular endothelial growth factor.
treatment response categories. None of the chemokine 
receptor expression levels differed significantly between 
the age tertiles (data not shown).
dIsCussIOn
Non-response to anti-VEGF remains an important issue 
with severe consequences for the patients. Both the 
innate and the adaptive immune systems are involved in 
the pathogenesis of AMD, but data on treatment response 
is sparse. Lechner et al found no correlation between 
leucocyte subtypes and number of injections in a 1-year 
follow-up period.24 Falk et al found no difference in 
CCR3+ granulocytes in patients with good BCVA response 
compared with those with poor BCVA response.16 Apart 
from these two studies, the relationship between mono-
cyte and lymphoid chemokine expression and treatment 
response remains unexplored.
Our findings demonstrate that non-responders after 
loading dose have a more complex peripheral chemo-
kine receptor profile compared with good responders. 
The concept of correlation networks provides a valuable 
and illustrative way of describing changes in an inte-
grated system like the immune system.8 25 There are 
some noticeable differences in correlations between 
single chemokine receptors, for example, CD14+CCR2+, 
which in the good responders only correlates to other 
monocyte-expressed receptors (CD14+CCR1+ and 
CD14+CCR5+), while it correlates to several lymphocyte 
receptors in the partial and non-response groups. Inter-
estingly, CCR2+ monocytes have been strongly linked 
to late-stage AMD.10–12 Retinal injury and inflammation 
increases intraocular levels of CCR2 ligand (CCL2),10 
and subsequently, CCR2+ monocytes are recruited to 
the inflamed retina.11 The correlations of CD14+CCR2+ 
could be a sign of an altered inflammation mechanism 
in the non-response group. The CD14+CCR2+ correla-
tions are also interesting in the context of our previous 
study, in which we showed an upregulation of CCR2 in 
patients with neovascular AMD, which was only signifi-
cant on non-classical proinflammatory monocytes.12 This 
upregulation has also been demonstrated by Grunin et 
al17 In the present study, we did not differentiate between 
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Table 2 Chemokine receptor expression level frequencies, %, median (IQR)
Response to anti-VEGF 
loading dose Good Partial Non-response P value*
CD14+CCR1+ 36.9 (19–58.8) 21.7 (12.3–31.5) 63.4 (58.2–57.2) 0.016†
CD14+CCR2+ 93.1 (82.1–97.1) 87.7 (79.4–94) 93.6 (89.2–98.4) 0.169
CD14+CCR3+ 0.4 (0.2–0.6) 0.2 (0.2–0.4) 0.2 (0.2–0.3) 0.103
CD14+CCR5+ 1 (0.3–2.1) 0.7 (0.4–1.4) 1.7 (0.4–2) 0.479
CD14+CXCR3+ 0.9 (0.6–1.7) 0.8 (0.4–1.4) 0.7 (0.4–2.3) 0.414
CD14+CX3CR1+ 35.9 (26.1–67.3) 40.1 (21.3–64.1) 24.3 (17.3–55) 0.500
CD4+CCR1+ 0.2 (0.2–0.4) 0.1 (0–0.2) 0.1 (0–9.5) 0.591
CD4+CCR2+ 5.1 (4.1–9) 5.1 (3.7–6.6) 7.2 (6.1–8.7) 0.479
CD4+CCR3+ 0.3 (0.2–0.4) 0.2 (0.1–0.3) 0.2 (0.1–0.2) 0.264
CD4+CCR5+ 2.7 (1.2–5.3) 1.8 (1.1–2.5) 4.2 (1.9–7.9) 0.130
CD4+CXCR3+ 2.5 (1.6–5) 3.2 (1–5.1) 2 (1.5–3) 0.645
CD8+CCR1+ 0.2 (0.2–0.4) 0.3 (0.1–0.6) 0.5 (0.1–2.8) 0.811
CD8+CCR2+ 7.8 (4.9–12) 7.5 (5.7–9.2) 7.8 (4.7–8.7) 0.687
CD8+CCR3+ 0.5 (0.4–0.8) 0.4 (0.4–0.7) 0.3 (0.1–0.4) 0.037†
CD8+CCR5+ 12.6 (4.5–23.1) 9.4 (4.7–14.7) 17 (9.6–23.9) 0.195
CD8+CXCR3+ 4 (1.9–6.3) 4.2 (1.3–8.6) 3.3 (1.4–9.1) 0.978
*Fisher’s exact test.
†Statistically significant.
Figure 2 Correlation networks of chemokine receptor 
expression on peripheral blood leucocytes. The correlation 
networks illustrate that patients with no response to anti-
VEGF treatment (increased CRT at follow-up) have a more 
complex chemokine receptor profile than patients with a 
partial response (CRT reduced by 0%–75% at follow-up) and 
patients with a good response to treatment (CRT reduced 
by <75% or full resorption of subretinal and intraretinal fluid). 
CRT, central retinal thickness; VEGF, vascular endothelial 
growth factor.
monocyte subsets, and the differences between the three 
groups might have been even clearer if we had isolated 
the non-classical monocyte subset.
Furthermore, we found an increased CD14+CCR1+ and 
a decreased CD8+CCR3+ expression level in the non-re-
sponse group. Previous research has demonstrated a 
significant increase of CCR1+ proinflammatory (non-clas-
sical) monocytes in patients with neovascular AMD 
compared with healthy controls.17 In a mouse model for 
retinal degeneration, CCR1 expression was found to be 
upregulated in photoreceptor cells.26 CCR1 expression 
has also been linked to other inflammatory degenerative 
diseases such as Alzheimer’s dementia.27 We also found a 
small change in the proportion of CD8+CCR3+ between 
the treatment groups. CCR3 has been studied as a poten-
tial target for neovascular AMD treatment with promising 
results on murine models.28 However, only a very small 
fraction of the CD8+ cells in our study expressed CCR3 
(0.3%–0.5%). In our gating strategy, we defined expres-
sion from negative isotype controls at 1% thresholds. 
This breeds a risk of interference when measuring low 
expression levels.
Important limitations should be considered in inter-
pretation of these data. This was an observational study, 
and we can only assume that a causal relationship exists 
regarding treatment response and the observed differ-
ences in the chemokine receptor expression. Changes 
in chemokine receptor expression could potentially 
be reactive or compensatory mechanisms. We did not 
measure the intraocular chemokine ligand levels and 
therefore cannot analyse ligand–receptor interaction in 
these patients.29 Also, the participants included received 
treatment with two different types of anti-VEGF, which 
might influence the individual response to the specific 
drug. Further, our study is limited in sample size, which 
unfortunately does not allow for multivariate analyses. 
Larger studies are warranted to allow multivariate anal-
yses to evaluate how these factors associate in more 
detail, to explore correlations between immunological 
phenotypes and features visible on detailed imaging 
such as subretinal fibrosis and hyperreflective foci, and 
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to explore potential impact in clinical practice and the 
prognosis we can give to our patients.
In conclusion, this study finds a more complex 
chemokine receptor profile on systemic monocytes and 
leucocytes in patients with neovascular AMD and lack 
of response to anti-VEGF treatment. This may implicate 
chemokines in anti-VEGF treatment failure and supports 
the idea of systemic immunology as a component of 
neovascular AMD pathogenesis and progression.
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